SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, today previewed several presentations taking place in conjunction with the annual American Society of Nephrology Kidney Week meeting, which will be held November 15 through November 20 in Chicago. The Company highlighted research exploring TIMP-2 and IGFBP7, which were identified 1 and validated 2 as biomarkers of acute kidney injury (AKI) risk in clinical studies leading to the commercialization of the Astute Medical's NephroCheck Test.
Hospitals are implementing risk assessment utilizing the NephroCheck Test and developing potential intervention strategies based on their own AKI protocols to address the danger that AKI poses to susceptible patients, including those suffering from systemic illness or injury, or who have recently undergone surgery. AKI is known to strike in up to 50 percent of critically ill patients, 3 heightening risk of mortality, lengthening intensive care stays and driving healthcare costs higher. 4 Kidney Week attendees can learn more about the NephroCheck Test at Astute Medical's exhibition booth #1523. "Physicians tell us that the NephroCheck Test is the first significant innovation in decades to gauge the risk of kidney injury before damage occurs," said Paul McPherson, Astute Medical chief scientific officer. "Now that the test is available, more and more hospitals are incorporating it into their kidney care protocols. The research presented at meetings such as Kidney Week is important to advancing AKI risk assessment, understanding the threat it poses to patients and improving the possibility of earlier intervention to preserve kidney health." Abstracts to be presented in clinical poster sessions include: